TGFB1 and colorectal carcinoma: Based on the above statements and comprehensive validations, we suggest that the novel TGF-β pathway clusters which were closed in conjunction with COMP in our study are reliable and have potential for leading novel immunological therapies and improving CRC patient prognosis.